Keylika
Biopharmaceutical company focused on drug discovery and drug delivery, employing AI-enabled de novo drug design and nanotechnology-based transdermal delivery technologies to generate breakthrough therapies.
About Keylika
Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes.
Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.
Products
Transdermal iron patch described as the world's first Rx skin patch to treat iron deficiency anemia (IDA), enabling direct absorption of proprietary iron into blood circulation...
New molecular entity (NME), a small molecule under 500 Da.
Platform synthesis technology for generating organometallic drugs for treating a wide range of therapeutic conditions including hematology, pain and inflammation, metabolic diso...
Security and compliance
No security details published yet
Keylika hasn't published certifications or security practices that we could find. Ask their team for audit reports.
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Claim Keylika